PDCD1 and non-small cell lung carcinoma: (21) reported increased TNF-α levels at the time before and 3 months after anti-PD-1 was correlated with improved response and prolonged survival (P=0.009) in 26 NSCLC patients treated with PD-1 inhibitors, while not association with PFS.